Genetic Technologies (ASX:GTG) Other Current Receivables: A$1.92 Mil (As of Jun. 2024)


What is Genetic Technologies Other Current Receivables?

Genetic Technologies ASX:GTG Other Current Receivables is A$1.92 Mil as of Jun. 2024.

Genetic Technologies's Other Current Receivables for the quarter that ended in Jun. 2024 was A$1.92 Mil.

Genetic Technologies's quarterly Other Current Receivables stayed the same from Dec. 2023 (A$0.00 Mil) to Mar. 2024 (A$0.00 Mil) but then increased from Mar. 2024 (A$0.00 Mil) to Jun. 2024 (A$1.92 Mil).

Genetic Technologies's annual Other Current Receivables declined from Jun. 2022 (A$1.98 Mil) to Jun. 2023 (A$1.73 Mil) but then increased from Jun. 2023 (A$1.73 Mil) to Jun. 2024 (A$1.92 Mil).

Genetic Technologies Other Current Receivables Related Terms

Genetic Technologies Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Other Current Receivables Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.99 1.98 1.73 1.92

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.92 0.00

Genetic Technologies Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$1.92 Mil mean?
Genetic Technologies (ASX:GTG) has a Other Current Receivables of A$1.92 Mil as of Jun. 2024. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Other Current Receivables too high?
Genetic Technologies' current Other Current Receivables is A$1.92 Mil.
How does Genetic Technologies' Other Current Receivables compare to LDDD and NOTV?
Genetic Technologies' Other Current Receivables of A$1.92 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Diagnostics & Research company?
A good Other Current Receivables depends on the Medical Diagnostics & Research industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current Other Current Receivables is A$1.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Other Current Receivables of A$1.92 Mil. The current Other Current Receivables is A$1.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Other Current Receivables is A$1.92 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.